Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study

BACKGROUND: Sorafenib was approved for treatment of unresectable hepatocellular carcinoma (HCC) in Japan in 2009. A prospective postmarketing all-patient surveillance (PMS) study was requested by Japanese authorities to confirm safety and effectiveness of sorafenib in Japanese HCC population. METHOD...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Gastroenterol
Autori principali: Kaneko, Shuichi, Ikeda, Kenji, Matsuzaki, Yasushi, Furuse, Junji, Minami, Hironobu, Okayama, Yutaka, Sunaya, Toshiyuki, Ito, Yuichiro, Inuyama, Lyo, Okita, Kiwamu
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Japan 2016
Soggetti:
Original Article—Liver, Pancreas, and Biliary Tract
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5037148/
https://ncbi.nlm.nih.gov/pubmed/26931117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00535-016-1173-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi